Patents by Inventor Ingvil Saeterdal

Ingvil Saeterdal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides
    Patent number: 8614177
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: December 24, 2013
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
  • PEPTIDES
    Publication number: 20110105721
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Application
    Filed: January 3, 2011
    Publication date: May 5, 2011
    Applicant: GEMVAX AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Peptides
    Patent number: 7863244
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: January 4, 2011
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Antigenic peptides derived from telomerase
    Patent number: 7794723
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: September 14, 2010
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
  • Peptides
    Patent number: 7192927
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: March 20, 2007
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
  • Peptides
    Publication number: 20070004632
    Abstract: Peptides from cancer related protein products of frameshift mutated genes which eliciting T cellular immunity for use in cancer vaccines and compositions for anticancer treatment.
    Type: Application
    Filed: August 3, 2006
    Publication date: January 4, 2007
    Applicant: GEMVAX AS
    Inventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal
  • Antigenic peptides derived from telomerase
    Publication number: 20060106196
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Application
    Filed: January 17, 2006
    Publication date: May 18, 2006
    Applicant: GemVax AS
    Inventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal, Stein Saeboe-Larsen
  • Antigenic peptides derived from telomerase
    Patent number: 7030211
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Grant
    Filed: June 30, 1990
    Date of Patent: April 18, 2006
    Assignee: GemVax AS
    Inventors: Gustay Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
  • Peptides
    Publication number: 20050074849
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Application
    Filed: February 12, 2004
    Publication date: April 7, 2005
    Applicant: GEMVAX AS
    Inventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal
  • Peptides
    Patent number: 6759046
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: June 4, 2001
    Date of Patent: July 6, 2004
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal